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Abstract 
Objectives: CD163 is a hemoglobin scavenger receptor on monocytes and macrophages, cleaved to 
soluble CD163 (sCD163) in the plasma following activation. In HIV+ adults, sCD163 is linked to 
non-AIDS morbidity and predicts mortality, but there is limited data in children. We investigated 
sCD163 levels in HIV+ children and their correlations with disease progression, immune activation 
and gut mucosal damage.  
Design and Methods:  We quantified sCD163 levels in Kenyan children aged 0-20 years with 
perinatal HIV infection, including 74 ART-naive (ART-) and 64 virally suppressed on ART (ART+), 
and 79 HIV unexposed-uninfected controls (HIV-). The cohort was divided into age groups 0-5 
(younger) and 5-20 (older) years. Correlations between sCD163 and HIV viral load, %CD8, 
CD4:CD8 ratio, markers of T cell activation and proliferation, and gut mucosal damage were also 
assessed. 
Results: ART- children have higher sCD163 levels compared to HIV- and ART+ children (p<0.01); 
ART+ have equivalent sCD163 levels to HIV- children. In a prospective analysis, sCD163 levels 
decreased in older ART- children after 12 months of treatment (p<0.0001). Regardless of age, 
sCD163 levels correlate with clinical disease progression measured by %CD4 T cells, CD4:CD8 T 
cell ratios and HIV viral load. Soluble CD163 levels directly correlate with T cell activation markers 
CD38, HLA-DR, and Ki67 (p<0.01).  
Conclusions: High plasma sCD163 levels in HIV+ children correlate with advancing disease and T 
cell activation. ART initiation normalizes sCD163 levels and may alleviate HIV-related morbidities 
and improve long-term pediatric outcomes. 
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Introduction 
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Globally, there are 36.9 million people living with HIV, of which 1.8 million are children[1]. 
With successful antiretroviral drugs, the major cause of HIV-related morbidity and mortality 
has shifted to non-AIDS complications, including cardiovascular disease and neurocognitive 
dysfunction[2, 3]. These co-morbidities are intricately linked to immune activation which 
begins early in HIV infection due to gut mucosal CD4 T cell destruction allowing microbial 
products to filter into systemic circulation and trigger immune responses mediated by 
monocytes and macrophages[4-8]. The subsequent chronic inflammation in the innate and 
adaptive immune systems drives HIV disease progression.  
CD163 is a hemoglobin scavenger receptor expressed primarily on monocytes and 
macrophages[4, 9]. Upon activation from exposure to pro-inflammatory stimuli such as 
lipopolysaccharide (LPS), Fcγ receptor crosslinking or oxidative stress, membrane-bound 
CD163 sheds via proteinase-mediated cleavage as soluble CD163 (sCD163)[9]. Thus, plasma 
levels of sCD163 reflect non-specific monocyte and macrophage activation[4, 10]. Membrane-
bound CD163 endocytoses haptoglobin-hemoglobin complexes and plays a role in 
erythroblast adhesion and immune sensing of bacteria[4, 9]. The function of sCD163 is 
undefined but has been proposed to be involved in inhibition of lymphocyte proliferation[9, 11, 
12]. As a hemoglobin scavenger sCD163 also plays an important role in extracellular iron 
recycling, which inhibits growth of iron-dependent bacterial pathogens[4, 29, 30]. 
HIV+ adults have elevated plasma sCD163 levels that persist despite antiretroviral treatment 
(ART)[4, 13-16]. High sCD163 plasma concentrations directly correlate with the presence and 
progression of carotid artery atherosclerosis, noncalcified coronary plaques, and coronary 
artery stenosis[10, 13, 16-18]. In both human and nonhuman primate studies, monocyte activation 
is also associated with HIV neuropathogenesis[19, 20]. Most importantly, sCD163 predicts all-
cause mortality in adults[10]. Thus, in adults, plasma sCD163 levels serve as a biomarker of 
HIV-related morbidity and mortality. 
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In children, the early onset of inflammation during immunologic and neurologic development 
leads to additional long-term comorbidities such as delayed cognitive development and early 
onset cardiovascular disease[21-24], yet there are limited data on plasma sCD163 levels in the 
pediatric population[25-27]. In a cohort of perinatally-infected HIV+ Kenyan children aged 0-
20 years, we report elevated sCD163 plasma concentrations that normalize to levels similar to 
HIV negative age-matched controls. High sCD163 plasma levels correlate with advancing 
HIV disease, gut mucosal disruption, and CD4 and CD8 T cell activation, as well as CD4 T 
cell proliferation.   
Materials and Methods 
Participants 
Ethical approval for this study was obtained from New York University and Kenyatta 
National Hospital/University of Nairobi. Written informed consent and verbal assent was 
obtained from all participants and/or parents. We enrolled 138 perinatally-infected HIV+ and 
79 HIV negative-unexposed children (HIV-) ages 2 months to 20 years from Bomu Hospital 
in Mombasa, Kenya between 2011-2012. HIV+ children included 74 ART naïve (ART-) and 
64 on ART for at least six months (ART+). Individuals with a recent pregnancy or acute 
illness or active Mycobacterium tuberculosis or malaria infection were ineligible for study 
entry.  
 
Subjects were subdivided into age groups of 0-5 (“0-5y” or “younger”) and 5-20 (“5-20y” or 
“older”) years old based on immunologic maturity. In both age cohorts HIV-, ART-, and 
ART+ were matched for age and gender (Table 1).  
Plasma Assays 
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Plasma levels of sCD163 and Intestinal Fatty Acid Binding Protein (I-FABP) were quantified 
by ELISA assay using Human sCD163 and I-FABP Duoset kits (R&D Systems). Plasma 
samples were diluted 1:100 for sCD163 and 1:1500 for I-FABP assays based on titration 
assays to fit within the standard curve range. Testing was performed in duplicate with 
average of duplicate results reported.  
Flow Cytometric Studies 
Cryopreserved PBMCs were thawed then evaluated with flow cytometry as described 
previously[28]. For intracellular cytokine staining, cells were activated with phorbol-myristate 
acetate (PMA) and Ionomicin in the presence of monensin for 5 hours, then fixed, 
permeabilized (eBioscience) and stained with intracellular antibodies. The following anti-
human antibodies were used: CD3, CD4, CD8, CD45RO, CD38, HLA-DR, Ki67 and IL-2. 
Stained cells were analyzed using LSRII flow cytometer (BD Bioscience) and FlowJo 
software (Tree Star). 
Statistical Analysis 
All statistical analyses were performed using GraphPad Prism software. Comparisons 
between multiple groups were performed with the Kruskal-Wallis followed by the two-stage 
linear step-up procedure of Benjamini, Krieger and Yekutieli to correct for multiple 
comparisons by controlling the False Discovery Rate. Multiple time points were evaluated 
with Wilcoxon matched-pairs signed-rank test. Correlations were assessed with the Spearman 
rank test. Threshold of significance for all tests was 0.05. 
Results 
High plasma sCD163 levels in ART- children normalize with treatment  
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Plasma sCD163 levels were higher in ART-0-5y than HIV-0-5y (p=0.004; Fig A1) and ART+0-5y 
(p=0.01; Fig A1). In the older cohort, ART-5-20y also had higher plasma sCD163 levels than 
HIV-5-20y (p<0.0001; Fig A2) and ART+5-20y (p<0.0001; Fig A2).  In a subset of ART- 
children who initiated treatment, after ~12 months of treatment, plasma sCD163 levels 
remained stable in ART-0-5y  children (Fig A3, A5) and decreased in ART-5-20y children 
(p<0.0001; Fig A4) to levels similar to HIV-5-20y children (Fig A6). 
Increased plasma sCD163 levels correlate with HIV disease progression 
To determine the clinical relevance of elevated sCD163 plasma levels, we examined 
correlations between sCD163 and clinical markers of HIV disease progression. In HIV+0-5y 
children, plasma sCD163 levels directly correlated with HIV viral load (p=0.004, r=0.37; Fig 
B1) and inversely correlated with %CD4 (p=0.003, r= -0.39; Fig B3) and CD4:CD8 ratios 
(p=0.02, r= -0.32; Fig B5). In HIV+5-20y children, plasma sCD163 levels correlated directly 
with viral load (p<0.0001, r=0.57; Fig B2) and inversely with %CD4 (p=0.004, r=-0.32; Fig 
1B4) and CD4:CD8 ratios (p=0.007, r= -0.30; Fig B6). 
Plasma sCD163 levels correlate with immune activation and gut mucosal disruption  
Coexpression of CD38 and HLA-DR marks T cell activation and predicts HIV disease 
progression. We investigated their correlations with sCD163. In HIV+0-5y children, plasma 
sCD163 levels directly correlate with CD38+HLA-DR+ CD4 T cells (p=0.01, r=0.36; Fig 
C1) and CD8 T cells (p=0.005, r=0.39; Fig C3). These correlations were similarly observed 
in HIV+5-20y children (CD4: p<0.0001, r=0.43; CD8: p=0.008, r=0.29; Fig C2, C4). We also 
determined whether sCD163 links to CD4 T cell proliferation by examining associations with 
Ki67, a marker of activated T cell proliferation, and IL-2, a cytokine that maintains 
homeostatic T cell proliferation. Plasma sCD163 concentrations directly correlated with Ki67 
levels in memory CD4 T cells (p=0.003, r=0.40; Fig D1) but not with IL-2 in HIV+0-5y 
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children (Fig D3). In HIV+5-20y children, sCD163 directly correlated with Ki67 (p=0.0009, 
r=0.37; Fig D2) and inversely correlated with IL-2 levels in memory CD4 T cells (p<0.0001, 
r= -0.44; Fig D4).  
We next investigated the relationship between plasma levels of sCD163 and I-FABP, a 
marker of gut mucosal disruption. In the HIV+0-5y children, there was no association between 
these markers (Fig E1), but in HIV+5-20y children there was a significant direct correlation 
(p=0.02, r=0.27; Fig E2). Last, we investigated whether sCD163 is associated with another 
monocyte activation marker, soluble CD14 (sCD14). A direct correlation between the two 
markers was observed in the HIV+0-5y children (p=0.0006, r=0.43; Fig E3), but no correlation 
was present in the HIV+5-20y children (Fig E4).  
Discussion 
We demonstrated that plasma sCD163 levels are elevated in untreated HIV+ children 
beginning in early childhood. In both age cohorts, ART+ children have sCD163 levels similar 
to HIV- controls. Regardless of age, higher plasma sCD163 levels correlate with worsening 
disease status, measured by decreasing CD4 T cell percentage and CD4:CD8 ratio, and 
increasing HIV viral load. Finally, sCD163 plasma concentrations in HIV+ children 
correlated with T cell activation and CD4 T cell proliferation, suggesting a link between 
innate and adaptive immunity. 
To our knowledge, this is the first report of sCD163 levels in a pediatric cohort aged less than 
5 years old with direct comparison to an older cohort. Remarkably, young children exhibited 
elevation of sCD163 levels similar to older children. Prior studies of sCD163 in HIV+ 
children include children with median age above 6 years and report high plasma sCD163 
levels that decrease with ART. Anaworanich et al. demonstrate in a Thai cohort with median 
age 6 years, that sCD163 levels in ART+ children were lower than ART- children[27]. Tuluc 
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et al. report in children aged 9-18 years plasma sCD163 levels significantly decrease after 
treatment with Raltegravir[26]. However, these two studies lack an HIV- control group to 
evaluate whether sCD163 plasma levels normalize. In our cohort, younger and older children 
normalized sCD163 levels in both cross-sectional and prospective analyses. Rudy et al. show 
plasma sCD163 levels significantly decrease after 48 weeks of ART, but remain significantly 
higher than HIV- controls[25], as opposed to our observation of similar sCD163 
concentrations in ART+ and HIV- children. We speculate the discrepancy may reflect 
different age cohorts, as Rudy’s findings in HIV+ youth aged 18-25 years matches previous 
adult sCD163 studies of persistently high sCD163 levels after treatment. It is possible that 
after a certain age it is no longer possible to reverse monocyte activation. Thus in children 
there may be a critical window to initiate ART in order to partially reverse monocyte 
activation. 
In HIV+ adults, sCD163 remains increased despite ART[4, 13-16]. These high sCD163 plasma 
levels have been linked to mortality, demonstrated by Knudsen et al. in a study of 933 virally 
suppressed HIV-infected adults in Denmark[10]. With each milligram per liter increase in 
sCD163 there was a 6% increase in mortality[10]. Interestingly, plasma sCD163 levels were 
not predictive of mortality in untreated HIV infection, when active HIV replication drives 
inflammation. Rather, they were only predictive for virally suppressed subjects whose 
inflammation is likely due to microbial translocation, coinfections or low-level replication of 
viral reservoirs[10]. While sCD163 levels were linked to all-cause mortality, the predictive 
value was slightly higher for cardiovascular causes of death[10, 31]. Whether sCD163 levels are 
linked to cardiovascular disease and mortality in children is unknown. We demonstrate that 
high plasma sCD163 concentrations correlate with worsening disease status, indicated by 
viremia, T cell activation, and decreasing CD4 percentages and CD4:CD8 ratios. In pediatric 
HIV, clinical parameters are associated with HIV-related morbidity while T cell activation 
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has been linked to increased risk of early onset cardiovascular disease and neurocognitive 
dysfunction. We speculate that monocyte activation may also be correlated with similar 
morbidity[21-24].  In adults, chronic inflammation is triggered by gut mucosal disruption. 
Interestingly, in our cohort plasma sCD163 levels associated with I-FABP levels in older but 
not younger children, suggesting there may be cumulative damage to the intestinal mucosa 
that triggers monocyte activation after longer durations of perinatal HIV infection.   
In summary, we demonstrate high plasma sCD163 levels in perinatally-infected HIV+ 
children that correlate with advancing HIV disease. Antiretroviral therapy reverses elevation 
of plasma sCD163 levels within 12 months. Plasma sCD163 concentrations correlate with T 
cell activation and proliferation, linking inflammation in the innate and adaptive immune 
systems. Early evidence of reversible monocyte activation in children supports the urgent 
implantation of immediate ART initiation in children as recommended by the WHO to 
alleviate the global burden of complications secondary to HIV infection and improve overall 
pediatric health outcomes.  
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FIGURE LEGENDS 
Figure 1: Soluble CD163 levels in HIV-infected children 
Children aged 0-5 years are shown in red and 5-20 years in blue. (A) Left (A1-2): comparison of 
plasma sCD163 concentrations in HIV unexposed-uninfected (HIV-), HIV-infected untreated (ART-), 
and HIV-infected treated (ART+) children. Center (A3-4): plasma sCD163 levels in ART- children 
who began treatment before (T0) and 12 months after (T1) treatment initiation. Right (A5-6): 
comparison between sCD163 levels in ART- at T0 and T1 and HIV- children. (B) Correlation 
between plasma sCD163 concentrations and HIV viral load (B1-2), percent CD4 T cells (B3-4), and 
CD4:CD8 ratio (B5-6) in HIV+ children. Correlation between plasma sCD163 concentrations and (C) 
percentage of CD38+HLA-DR+ cells on CD4 (C1-2) and CD8 (C3-4) T cells, (D)  Ki67 (D1-2) and 
IL-2 (D3-4) levels in CD45RO+ CD4 T cells , and (E) plasma intestinal fatty acid binding protein 
(E1-2) and sCD14 (E3-4) levels in HIV+ children.  
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Table 1. Subject Characteristics 
 
*Median values with upper and lower quartile range 
(a) Kruskal-Wallis test; (b) Chi-Square test; (c) two-sided Mann-Whitney test 
 
HIV- ART- ART+ p 
YOUNGER COHORT (0-5 years) 
n 34 29 30   
Age (years)* 2.5 (1.2-3.5) 2.0 (1.1-3.2) 3.1 (2.2-3.5) NSa
Female (n) 20 (55%) 17 (56%) 12 (40%) NSb 
%CD4* 33 (29-38) 21 (14-32) 32 (27-35) p=0.0001a 
HIV log copies/ml*  5.3 (4.1-5.8) 2.0 (2.0-2.7) p<0.0001c 
OLDER COHORT (5-20 years) 
n 45 45 34   
Age (years)* 12 (9.4-16) 11 (8.6-14) 12 (8.3-13) NSa 
Female (n) 18 (40%) 25 (57%) 20 (60%) NSb 
%CD4* 38 (33-42) 24 (13-28) 32 (26-40) p<0.0001a 
HIV log copies/ml*  4.8 (4.2-5.2) 2.0 (2.0-2.0) p<0.0001c 
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